Scalper1 News
ZS Pharma (ZSPH) hit a new high Friday, following the appointment of several new executives that will help the biotech company prepare for drug trials. The biopharmaceutical company is focused on developing and commercializing drugs to treat renal, cardiovascular, liver and metabolic diseases. ZS Pharma stock stock rose 8.3% Friday to close at a new high of 50.51. The stock is up 180% from its June 18 initial public offering, which raised $107 Scalper1 News
Scalper1 News